HMGB1 and Sepsis: Although the reason for no therapeutic effect of SGC-CBP30-0.5 h therapy group remains to be elucidated, it can be predicted that administrated with SGC-CBP30 at 0.5 h post sepsis modeling, it is difficult to maintain effective blood concentrations to combat the onset of HMGB1-mediated inflammatory storms at the “late-phase” of lethal sepsis.